Home
Contact Us
Site Map
Skip to content
About PDL
About PDL
PDL History
Management
Board of Directors
Dividend FAQs
Careers
Contact Us
Technology & Products
Technology & Products
What are Antibodies?
How do Antibodies Work?
What are Humanized Monoclonal Antibodies?
Monoclonal Antibody Therapy
Commercialized Products
Product Pipeline
Royalty Revenue
Royalty Revenue
Historical Product Sales Revenue
Historical Royalty Revenue
Manufacturing Split Genentech / Roche & Novartis
Investor Relations
Investor Relations
Press Releases
Events & Presentations
Corporate Governance
Financial Information
SEC Filings
Stock Information
Investor FAQs
Contact Us
News & Resources
News & Resources
News Releases
Company Presentations & Events
CEO Newsletter
Site Map
About PDL
PDL History
Management
John McLaughlin
Christopher L. Stone
Karen Wilson
Board of Directors
Frederick Frank
Jody Lindell
John McLaughlin
Paul Sandman
Harold Selick, Ph.D.
Contact Info
Technology & Products
What are Antibodies?
How do Antibodies Work?
What are Humanized Monoclonal Antibodies?
Monoclonal Antibody Therapy
Commercialized Products
Avastin
®
(bevacizumab)
Herceptin
®
(trastuzumab)
Lucentis
®
(ranibizumab)
Xolair
®
(omalizumab)
Tysabri
®
(natalizumab)
Synagis
®
(palivizumab)
Mylotarg
®
(gemtuzumab ozogamicin)
Actemra
®
/RoActemra (tocilizumab)
Product Pipeline
Bapineuzumab
Solanezumab
Motavizumab
Teplizumab
Trastuzumab-DM1
Royalty Revenue
Historical Product Revenue
Historical Royalty Revenue
Manufacturing Split – Genentech/Roche
Investor Relations
Corporate Governance
Stock Information
Annual Report & SEC Filings
Analysts
Estimates
Fundamentals
Info Request
News & Resources
News Releases
Company Presentations & Events
Product News Archive
Comments are closed.
